Spyre Therapeutics, Inc. (SYRE) Operating margin 2016–2023
Spyre Therapeutics, Inc. (SYRE) operating margin by fiscal year — reported operating income divided by reported revenue.
-27348.0%FY2023 · since FY2016: -473.3% → -27348.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -27348.0% | -23707.7 pp |
| FY2022 | -3640.2% | -3289.9 pp |
| FY2021 | -350.3% | — |
| FY2018 | -1169.3% | -637.6 pp |
| FY2017 | -531.7% | -58.4 pp |
| FY2016 | -473.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice